TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05775159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: CTLA-4/Anti-PD-1 Bispecific Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: CTLA-4/Anti-PD-1 Bispecific Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: CTLA-4/Anti-PD-1 Bispecific Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: CTLA-4/Anti-PD-1 Bispecific Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: anti- PD-1 and TIGIT bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: anti- PD-1 and TIGIT bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: anti- PD-1 and TIGIT bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2, IV infusion
Study: NCT04284787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05775159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2, IV infusion
Study: NCT05798117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YTB323
Description: Single infusion of YTB323
Study: NCT06550804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-TEAM
Description: Participants randomized to the intervention arm will receive the proposed intervention, which involves an electronic adherence device called Wisepill and triaged text alerts to the user, the social support, and the case manager for same day, two day, and seven day device non-openings.
Study: NCT05933356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scheduled activities
Description: scheduled activities

Intervention type: OTHER
Group type: OTHER
Intervention: scheduled activities
Description: scheduled activities
Study: NCT04284787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05984030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Navigation Services
Description: Trained professional PrEP navigators will connect with intervention arm participants following study onboarding. Primary navigator responsibilities include helping participants engage in PrEP care, assisting with completing necessary paperwork for insurance, referral to PrEP care, and application for drug assistance programs, as needed. Navigation services will be available to participants for the first 6 months of participation (active intervention period). Navigation services are tailored to the individual needs of each intervention arm participant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth PrEP Services Referral
Description: PrEP Navigators can link interested intervention arm participants to telehealth PrEP services via self-referral. The study facilitates referral for intervention arm participants to pre-existing telehealth PrEP services. The telehealth PrEP services participants receive are not provided, financed, or staffed by the study. Participants will receive telehealth PrEP services via the technology platform or service that the provider typically employs. PrEP clinical eligibility, visit frequency, monitoring labs, and all other PrEP management will be at the discretion of the established PrEP provider. PrEP navigators can assist with appointment scheduling, reminders, and other provider-access issues, as requested, for the first 6 months of study participation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthMpowerment Digital Health Intervention - Enhanced
Description: The Enhanced version of the HealthMpowerment Digital Health Intervention includes all features from the Basic version, plus the following additional features: Interactive skill-building health activities; social support newsfeed/group chat; Ask the Expert anonymous health question and answer; Medication Tracker; Health Behavior Tracker; Gamification features for participant engagement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HealthMpowerment Digital Health Intervention - Basic
Description: The Control Arm version of the HealthMpowerment Digital Health Intervention includes: Study Timeline and Calendar, publicly-available PrEP locator feature, Dried Blood Spot self-collection kit ordering, Educational Health Resource Center.
Study: NCT06425055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonafexor
Description: * One tablet of a low dose of vonafexor QD from Day 1 to Week 4~* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8~* One tablet of a high dose of vonafexor QD from Week 9 to Week 24
Study: NCT05780372

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy will be arranged by the physician-in-charge according to the NCCN guideline, patient's stage and physical condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy will be arranged by the physician-in-charge according to the NCCN guideline, patient's stage and physical condition.
Study: NCT06551506

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abrysvo
Description: A maternal RSV vaccine based on the prefusion F protein administered during pregnancy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abrysvo
Description: A maternal RSV vaccine based on the prefusion F protein administered during pregnancy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abrysvo
Description: A maternal RSV vaccine based on the prefusion F protein administered during pregnancy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Beyfortus
Description: A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Beyfortus
Description: A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Beyfortus
Description: A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants
Study: NCT05654675

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG PET/CT
Description: Besides the standard care FDG PET/CT examination, subjects receive a dynamic whole body PET/CT examination.
Study: NCT05715463

Intervention type: OTHER
Group type: OTHER
Intervention: Resource sheets
Description: Arm 1 is the control arm which will receive the standard of care resource sheets. Patients in this arm will receive cultivated resource sheets for any SDoH-related needs that they screen positive for or request additional information on.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Resource Specialist
Description: The CRS will help guide patients to the necessary community-based resources to help address their specific SDoH needs that impact their health and their ability to access sustained, high quality medical care. This may include forms to arrange for subsidized transportation to and from medical appointments or applications for Section 8 housing. The community resource specialist will reach out to patients in Arm 2 a minimum of 2 times per month, with more interactions guided by patients needs. All outreach attempts and contacts will be documented in EPIC and in REDCap. Actions taken by the CRS will be shared with members of the patient's healthcare team as appropriate (with EPIC notes routed to the rheumatologist and primary care provider, and if indicated and relevant, a social worker, nutritionist, prior CRS, nurse or mental health provider if previously involved in the patient's care).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Navigator
Description: The nurse navigator will both work with the CRS to connect the patient with community-based resources, independently connect the patient with relevant resources, and also help coordinate the patient's medical care and mental health needs. The nurse patient navigator will conduct her own needs assessment (the nurse navigator high risk assessment questionnaire at the time of the first conversation with the patient, originally developed as part of the MGB integrated care management program) and her actions will be guided by their responses. She will reach out to patients a minimum of 2 times per month with an increase in communication around patient appointments as reminders, and more frequent communication on a case-by-case basis depending on active illnesses, frequency of outpatient appointments, and needs of the patient. All outreach attempts and contact will be documented in EPIC and in REDCap and similar to the CRS, be shared via EPIC with the care team as indicated.
Study: NCT06561685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4050784
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4050784
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4050784
Description: Oral
Study: NCT06179108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-102
Description: LB-102 is a dopamine D2/3 and 5HT7 antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-102
Description: LB-102 is a dopamine D2/3 and 5HT7 antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-102
Description: LB-102 is a dopamine D2/3 and 5HT7 antagonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LB-102
Description: LB-102 is a dopamine D2/3 and 5HT7 antagonist.
Study: NCT05767047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Oral tablets or liquid suspension
Study: NCT06357299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Bottle Size
Description: Small sized bottle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Bottle Size
Description: Small sized bottle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Bottle Size
Description: Standard sized bottle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Bottle Size
Description: Standard sized bottle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clear Bottle
Description: Clear bottle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clear Bottle
Description: Clear bottle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opaque Bottle
Description: Opaque bottle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opaque Bottle
Description: Opaque bottle
Study: NCT05130762

Intervention type: DEVICE
Group type: OTHER
Intervention: BD PureHub™ Disinfecting Cap Placements: Attachments/removals
Description: Attachment/Removals of BD PureHub™ Disinfecting Cap
Study: NCT05693740

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated crosslinking (ACXL)
Description: Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated crosslinking (ACXL)
Description: Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.
Study: NCT05645536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOL2506
Description: Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg once daily or 10 mg 2 times daily - either tablet of solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: One 2.5 mg tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole Tablets
Description: One 1 mg tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane Tablets
Description: One 25 mg tablet taken orally once daily
Study: NCT06170034

Intervention type: BEHAVIORAL
Intervention: Satisfaction questionnaire
Description: Satisfaction questionnaire to assess how TIA patients feels about their medical care.

Intervention type: OTHER
Intervention: Medical care questionnaire
Description: Recording appointments and results of examinations and consultations in TIA management
Study: NCT06634719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juveena Hydrogel System
Description: The Juveena Hydrogel System is a single-use device that is instilled into the endometrial cavity as a liquid and sets up as a gel intrauterine tamponade within seconds.
Study: NCT06636123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Agent Administration
Description: GZ17-6.02 will be taken orally with a high-fat meal at a fixed dose of 375 mg twice daily each day of a 28-day cycle, continuing until progression or intolerable toxicity
Study: NCT05789316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ototoxicity Screening Protocol
Description: The ototoxicity screening protocol contains a functional and objective component. The functional component is the Hearing Handicap Inventory for the Elderly - Screening Version (HHIE-S). The objective component will be pure tone audiometry. A 2 kHz tone at 40 dB will play through over-the-ear headphones and subjects will indicate whether they heard it.
Study: NCT04431726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.~At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.~During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first.
Study: NCT05697302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Interviews will be held twice a week in the first two weeks of the first month, once a week in the following weeks, and once every two weeks in the second month, 8 times in a total of 2 months. The number of 8 interviews planned in the research may increase specifically for the situation of the mother and the baby. Interviews will be held at the mothers' homes or at the Family Health Center. An individualized message will be sent to mothers, two days a week, in accordance with their mobile communication tool, relactation needs. In addition, if the mothers request, they can call the researcher via mobile communication via video or voice and receive live support regarding their questions and questions.
Study: NCT05403372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAS-C System
Description: The InterShunt PAS-C System is a transcatheter system that creates a shunt by excising tissue from the interatrial septum resulting in a left to right atrial shunt that off-loads elevated left atrial pressure, potentially reducing symptoms and improving quality of life. The PAS-C System does not require a permanent implant to maintain patency of the interatrial shunt.
Study: NCT04917952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR)
Description: * Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, 80% at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the intervention group will receive an exercise protocol with blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Blood flow restriction will be applied at 80% by using pressure cuffs. The cuffs will be applied to the proximal thigh. Cuff pressure needed for a 100% vascular occlusion will be determined for each individual at a seated and relaxed position.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Blood Flow Restriction (sham BFR)
Description: * Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, Sham BFR, 10mm Hg at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the control group will receive an exercise protocol with sham blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Sham technique for blood flow restriction will be applied by using pressure cuffs inflated at 10mm Hg. The cuffs will be applied to the proximal thigh. Cuff pressure will be applied for each individual at a seated and relaxed position.
Study: NCT04955223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yinhu Qingwen Granules
Description: For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
Study: NCT04777149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial Random Noise Stimulation (tRNS)
Description: Two electrodes will be placed over the targeted areas on participant's head. A current of random frequency and intensity will be delivered. TRNS will be applied during the first 20 min of functional task practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered. TDCS will be applied during the first 20 min of functional task practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham-stimulation
Description: Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered for 1- 2 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham-stimulation
Description: Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered for 1- 2 min.
Study: NCT05318430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous closed-suction drainage device
Description: This subcutaneous closed-suction drainage device was designed to be placed subcutaneously when surgeons have completed all intra-abdominal operations and are about to suture subcutaneous layer and skin
Study: NCT05614427

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Innova Lateral Flow Test
Description: Lateral flow test performed on anterior nasal or buccal swabs

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Innova Lateral Flow Test
Description: Lateral flow test performed on anterior nasal or buccal swabs